PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 53 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $31,000 | +3.3% | 8,891 | +0.3% | 0.00% | – |
| Q4 2020 | $30,000 | -6.2% | 8,867 | -2.8% | 0.00% | – |
| Q3 2020 | $32,000 | -23.8% | 9,122 | -0.3% | 0.00% | – |
| Q2 2020 | $42,000 | +55.6% | 9,150 | +12.6% | 0.00% | – |
| Q1 2020 | $27,000 | -48.1% | 8,123 | -5.5% | 0.00% | – |
| Q4 2019 | $52,000 | +44.4% | 8,592 | -0.8% | 0.00% | – |
| Q3 2019 | $36,000 | -68.7% | 8,664 | -0.7% | 0.00% | – |
| Q2 2019 | $115,000 | – | 8,725 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 1,607,044 | $4,194,000 | 0.48% |
| NEA Management Company, LLC | 6,643,704 | $17,340,000 | 0.35% |
| Platform Technology Partners | 251,723 | $657,000 | 0.29% |
| DAFNA Capital Management LLC | 378,611 | $988,000 | 0.25% |
| Avidity Partners Management LP | 4,405,000 | $11,497,000 | 0.24% |
| Endurant Capital Management LP | 360,078 | $940,000 | 0.23% |
| Rock Springs Capital Management LP | 2,581,299 | $6,737,000 | 0.16% |
| RA Capital Management | 2,850,000 | $7,439,000 | 0.13% |
| New Legacy Group, LLC | 240,575 | $628,000 | 0.12% |
| XTX Topco Ltd | 15,574 | $41,000 | 0.02% |